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OBJECTIVES The study defined the incidence of cerebral hyperperfusion syndrome and intracranial hemorrhage
(ICH) and the risk factors for their development following carotid artery stenting (CAS).
BACKGROUND Hyperperfusion syndrome and ICH can complicate carotid revascularization, be it endarter-
ectomy or CAS. Although extensive effort has been devoted to reducing the incidence of
ischemic stroke complicating CAS, little is known about the incidence, etiology, and
prevention strategies for hyperperfusion and ICH following CAS.
METHODS We retrospectively reviewed the prospective database of 450 consecutive patients who were
treated with CAS in our department to identify patients who developed hyperperfusion
syndrome and/or ICH.
RESULTS The mean age of the patients was 72.7  10.9 years, and the mean diameter narrowing was
84  12.8%. Five (1.1% [95% confidence interval 0.4% to 2.6%]) patients developed
hyperperfusion. Three (0.67%) of the five developed ICH. Two of these patients died
(0.44%). Symptoms developed within a median of 10 h (range, 6 h to 4 days) following
stenting. All five patients had correction of a severe internal carotid stenosis (mean 95.6 
3.7%) with a concurrent contralateral stenosis 80% or contralateral occlusion and peri-
procedural hypertension. These same risk factors are involved in cerebral hyperperfusion
following carotid endarterectomy. The use of platelet glycoprotein IIb/IIIa receptor blockers
did not appear to increase the risk ICH.
CONCLUSIONS The hyperperfusion syndrome occurs infrequently following CAS, and ICH occurs in 0.67%
of patients. Patients with severe bilateral carotid stenoses may be predisposed to ICH,
particularly if there is concurrent arterial hypertension. Patients with these factors may require
more intensive hemodynamic monitoring after CAS, including prolongation of hospitaliza-
tion in some cases. (J Am Coll Cardiol 2004;43:1596–601) © 2004 by the American
College of Cardiology Foundationa
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warotid artery stenting (CAS) is emerging as a potential
lternative to carotid endarterectomy (CEA) (1,2). Post-
urgical hyperperfusion syndrome (HPS) and intracranial
emorrhage (ICH) have been well described following
EA and are associated with significant morbidity and
ortality (3–11). Little is known about the incidence of
PS and ICH following CAS (12–17). It is also not
nown if the risks of HPS and ICH are comparable
etween CEA and CAS, especially as anticoagulants and
otent antiplatelet regimens are used during CAS. Im-
rovements in endovascular techniques and the develop-
ent of emboli-prevention devices have markedly re-
uced the incidence of ischemic stroke following CAS; as
result, HPS and ICH may become major causes of
orbidity and mortality following endovascular carotid
rtery revascularization (1,2).
To study the incidence and clinical and laboratory pre-
ictors of HPS and ICH we reviewed a prospective database
From the *Department of Cardiovascular Medicine and †Department of Neurol-
gy, The Cleveland Clinic Foundation, Cleveland, Ohio.
Manuscript received August 20, 2003; revised manuscript received December 5,o003, accepted December 9, 2003.t our institution to identify patients who developed ICH
ollowing CAS.
ETHODS
e retrospectively reviewed a prospectively collected data-
ase of all patients who underwent CAS in our department
o find patients who had HPS or ICH. The database
ncluded demographic information, clinical history, symp-
omatic status of the internal carotid artery (ICA), angio-
raphic findings, procedural details, adjunctive antithrom-
otic/anticoagulant agents used, and peri-procedural events.
erioperative and follow-up data on neurological events
ncluding any transient ischemic attack, stroke, seizure, or
hange in neurological status were also collected. Following
ospital discharge, patients paged the interventional fellow
n-call if they developed any symptoms; all such events were
aptured into the database.
Hyperperfusion syndrome was defined by the occurrence,
ither singly or in combination, of ipsilateral (to the treated
rtery) temporal, frontal or retro-orbital throbbing headache
ith or without nausea, vomiting, ipsilateral focal seizures,
r focal neurological deficit without radiographic evidence
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May 5, 2004:1596–601 Hyperperfusion Syndrome Following Carotid Stentingf infarction. Intracranial hemorrhage was defined by com-
uted tomography evidence of punctate or confluent hyper-
ensities consistent with blood within the parenchyma of
he cerebral hemispheres or within the subarachnoid space.
A neurologist evaluated all patients before and after the
rocedure to determine whether any patients showed neu-
ological signs or symptoms. The technique of CAS has
een described elsewhere (18) but evolved over the three
ears of this study. The major change was the introduction
f mechanical emboli-prevention devices, which led to
essation of the use of platelet glycoprotein IIb/IIIa receptor
lockers (GPIIb/IIIa). The doses and agents used for
PIIb/IIIa blockade varied, but when they were utilized the
oal was 75% platelet inhibition as measured by a bedside
est of platelet aggregation. Patients were pretreated with
spirin 325 mg/d and clopidogrel 75 mg/d for at least one
eek. In cases of urgent intervention, a clopidogrel 300-mg
oad was given. All patients were treated with heparin
ntraoperatively with a bolus of 50 U/kg with additional
oses as necessary to achieve an activated clotting time
ACT) of 250 to 325 s. Procedural success was defined as a
ost-stent luminal narrowing of30% using the North Amer-
can Symptomatic Carotid Endarterectomy (NASCET)
ethod (19). All patients underwent CAS as part of
nstitutional review board-approved protocols.
Based on a literature review of HPS and ICH following
EA, hypertension, the severity of the treated stenosis, and
he presence of contralateral stenosis or occlusion were
dentified as potential risk factors (5,6,8,9,11,20). Statistical
nalysis was performed using the SAS statistical package
Version 8, SAS Institute, Cary, North Carolina). For
ontinuous variables a Mann-Whitney test was performed.
chi-square proportion test was used to test for indepen-
ence among the treated stenosis severity, the presence of
ontralateral occlusion or stenosis 80%, and hypertension.
ssuming that the presence of hyperperfusion has an
nderlying normal distribution we utilized a Boolean “and”
tatistic of the three criteria (i.e., 1  the presence of all
hree criteria; 0  two or less criteria) to test, at the 99.5%
evel, whether the “and” statistic (i.e., the presence of all
Abbreviations and Acronyms
ACT  activated clotting time
CAS  carotid artery stenting
CBF  cerebral blood flow
CEA  carotid endarterectomy
GPIIb/IIIa  platelet glycoprotein IIb/IIIa receptor
blockers
HPS  hyperperfusion syndrome
ICA  internal carotid artery
ICH  intracranial hemorrhage
MCA  middle cerebral artery
SBP  systolic blood pressure
TCD  transcranial Doppler ultrasoundhree criteria) and hyperperfusion are uncorrelated. sESULTS
ata from 450 consecutive patients were analyzed. The
aseline characteristics are presented in Table 1. The
ndication for CAS was at least one high-risk criterion for
EA, most frequently previous CEA or active coronary
rtery disease. Isolated hyperperfusion occurred in two
0.44%) patients and ICH occurred in three (0.67%) pa-
ients, for a combined incidence of 1.1% (95% confidence
nterval 0.4% to 2.6%). All five patients had hypertension.
he other baseline characteristics were similar between the
PS and non-HPS patients.
Table 2 details the lesional and technical characteristics.
f the 445 patients without HPS, 228 (51.2%) received a
PIIb/IIIa and 216 (48.5%) were treated with an emboli-
able 1. Patient Characteristics
Patient Characteristics
Without
Hyperperfusion
With
Hyperperfusion
ge (yrs) 72.7  10.9 72.7  4.5
ge range (yrs) 36–90 67–79
therosclerosis risk factors, n (%)
Coronary artery disease 255 (78.9) 3 (60)
Hypertension 339 (76.2) 5 (100)
Cigarettes 225 (69.7) 4 (80)
Hyperlipidemia 197 (61.6) 4 (80)
Diabetes mellitus 176 (54.5) 3 (60)
igh-risk criteria, n (%)
Previous carotid
endarterectomy
179 (55.4) 2 (40)
Pre-open heart surgery 96 (29.7) 0
Congestive heart failure 67 (20.7) 0
Chronic obstructive pulmonary
disease
55 (17) 2 (40)
Neck radiation therapy 43 (13.3) 1 (20)
Chronic renal insufficiency 16 (5) 0
able 2. Lesion and Technical Characteristics
Technical Characteristic
Patients
Without
HPS
(n  445)
Patients
With
HPS
(n  5)
PIIb/IIIa blockade, n (%)
Abciximab 208 (46.7) 2 (40)
Eptifibatide 20 (4.9) 0
Total 228 (51.2) 2 (40)
mboli-prevention device, n (%) 216 (48.5) 3 (60)
ymptomatic status, n (%)
Transient ischemic attack 162 (36.4) 2 (40)
Stroke 116 (26.1) 2 (40)
Asymptomatic 167 (37.5) 1 (20)
rocedural success, n (%) 97.8% 100%
ontralateral disease, n (%)
Occlusion 58 (13) 2 (40)
Stenosis 80% 26 (5.8) 3 (60)
Total 84 (18.9) 3 (100)
rimary lesion, mean % stenosis  SD
Severity 83.8  11.3% 95.6  3.7%*
p  0.001.
GPIIb/IIIa  platelet glycoprotein IIb/IIIa receptor; HPS  hyperperfusionyndrome.
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Hyperperfusion Syndrome Following Carotid Stenting May 5, 2004:1596–601revention device. Two of the three patients with ICH had
eceived a GPIIb/IIIa, whereas one was treated with an
mboli-prevention filter. The two patients with isolated
PS did not receive a GPIIb/IIIa but were treated with an
mboli-prevention filter. Two-thirds of the patients in both
roups had symptomatic carotid stenoses.
The treated stenosis was significantly more severe in the
ve patients with HPS (mean stenosis 95.6 3.7%) than in
hose without HPS (mean stenosis 83.8  11.3%), p 
.001. All five patients with HPS had 80% contralateral
CA stenosis (n  3) or a contralateral ICA occlusion (n 
). Of those without HPS, only 84/445 (18.9%) had similar
ontralateral disease. All five of the patients with HPS had
treated stenosis of 90% luminal narrowing, a contralat-
ral stenosis of 80% or occlusion, and hypertension. Of
he patients without HPS only 26 of 445 (5.8%) had these
hree characteristics. The results of the Boolean analysis of
he null hypothesis yielded a sample correlation between the
oolean statistic and the presence of hyperperfusion of
.40161. Thus, the hypothesis that our Boolean “and”
tatistic (i.e., the presence of all three criteria) and hyper-
erfusion are uncorrelated must be rejected, and this sug-
ests that hyperperfusion is associated with the presence of
ll three criteria. The risk of HPS if a patient had all three
haracteristics was 16% (5/31).
eview of cases. Intracranial hemorrhage occurred without
ntecedent symptoms immediately after the intervention in
ne patient (Fig. 1). In the other four cases, severe,
psilateral, retro-orbital throbbing headache developed be-
ween six h and four days postoperatively (median 10 h).
wo of the patients developed postoperative hypertension
systolic blood pressure [SBP] 180), both of whom
ubsequently developed ICH. In the three patients who
igure 1. Preoperative angiograms (A and B) from Patient 1 show a 99% s
f the ICA compared with the external carotid artery (arrowhead in A) as w
omography scan of the brain (C) performed 1 h following left carotid stentteveloped a headache while hospitalized, intravenous treat-
ents were immediately initiated to maintain the minimum
BP that resulted in resolution of symptoms, which was
120 mm Hg in all three cases. Clopidogrel and aspirin
ere withheld until the symptoms resolved. This occurred
ithin 12 to 36 h in all three cases. Upon symptom
esolution, antiplatelet agents were restarted. Patients and
heir families were instructed to strictly adhere to their
ntihypertensive regimen and to monitor blood pressures at
east twice daily, with instructions to call the interventional
ellow on-call for any recurrence of symptoms or blood
ressure values 140/90 mm Hg. Both patients who
eveloped ICH after discharge did not take their antihy-
ertensive medicines. One patient presented with a seizure
nd confusion on the fifth postoperative day, and the other
resented with recurrent severe headache, nausea, and
omiting followed by rapidly progressive hemiparesis and
oma on postoperative day three (Figs. 2 and 3). Two of the
hree patients with ICH died; the third survived with a
oderate disability.
ISCUSSION
his current series is the largest study to date focusing on
yperperfusion and ICH following CAS. We found an
ncidence of HPS of 1.1%, and the incidence of ICH was
.67%. Intracranial hemorrhage following CAS was associ-
ted with a high mortality and morbidity rate. The five
atients from our institution who developed HPS had
everal characteristics in common: all had a 90%-treated
CA stenosis and all had severe stenoses (80%) involving
he contralateral carotid artery. All five patients were hyper-
is of the left internal carotid artery (ICA) (arrow in A) with delayed filling
an 80% stenosis of the origin of the right ICA (arrow in B). Computerized
ows a large basal ganglia hemorrhage with mild subarachnoid hemorrhage.tenos
ell asensive at baseline, and two of them developed significant
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May 5, 2004:1596–601 Hyperperfusion Syndrome Following Carotid Stentingostprocedural hypertension preceding the onset of ICH.
lthough one patient developed ICH immediately postpro-
edure, the others developed typical hyperperfusion syn-
rome features within days of the intervention. Progression
o neurological dysfunction and ICH occurred in two of the
our patients.
Although there are no published, systematic analyses of
PS in CAS patients, three groups have published their
xperience with ICH following cervicocranial interventions.
he first two reports consisted of heterogeneous patient
opulations (13,15). The series by Schoser et al. (13)
igure 2. Preoperative angiograms (A and B) from Patient 2 show a 99% s
arotid artery stenosis (arrowhead in A). The right ICA is occluded at its
can (C) shows a left frontal lobe, confluent hematoma.
igure 3. Angiograms from Patient 3 show a near occlusive lesion of the r
CA (arrow in B). Three days following right carotid stenting, a compute
ith midline shift and intraventricular hemorrhage.onsisted of 86 patients who were treated with ICA angio-
lasty alone, and the series of Meyers et al. (15) reported on
heir stenting results in 140 patients, only 66 of whom had
arotid interventions. In these two series the incidence of
CH was 1.4% and 2.3%, respectively. Meyers et al. (15) did
eport on isolated hyperperfusion in their patients, and they
ound the incidence to be 5%. The third report described 90
atients undergoing CAS without emboli-prevention de-
ices (16). The stenting protocol included a 100 U/kg
eparin bolus with a 1,000 to 2,000 U/h infusion. The
ncidence of ICH was 3.8%, with a mean ICA stenosis of
is of the left internal carotid artery (ICA) (arrow in A) distal to a common
(arrow in B). Four days following stenting, a computerized tomography
nternal carotid artery (ICA) (arrow in A) and an 80% stenosis of the left
tomography of the brain (C) reveals a large right-hemisphere hematoma,tenos
originight i
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Hyperperfusion Syndrome Following Carotid Stenting May 5, 2004:1596–6015% in those with ICH. The investigators concluded that,
ompared with CEA, CAS is associated with a higher rate
f ICH. The results of these three series likely do not reflect
he true incidence of hyperperfusion and ICH following
AS. The reasons for this are multiple: 1) The first two
eries included patients who had interventions of vessels
ther than the carotid artery, including intracranial arteries.
) The heparin doses used in the series described by Meyers
t al. and Morrish et al. (16) were very high, and heparin
as continued for 12 h postoperatively in the Meyers et al.
eries (15). The investigators did not report on the intraop-
rative ACTs, which were likely much higher than those in
ur patients who received a 50% lower dose of heparin. 3)
astly, because recent ischemia is a known risk factor for
CH, the lack of emboli-prevention devices in all three
eries may have increased the risk of ICH.
Reports of ICH following CEA first appeared in the 1960s,
ut the term “hyperperfusion hemorrhage” was initially coined
y Sundt et al. (4) in 1981 (21,22). They measured increases in
erebral blood flow in patients who developed the clinical
yndrome after CEA. Hyperperfusion is now a well-
ecognized complication of CEA (3,5,7,10,11,23). The inci-
ence of ICH associated with HPS following CEA is 0.3% to
.2% (3–5,7,11,23). The rates of occurrence in our series are in
eeping with these figures, suggesting that there is not an
ncreased risk of ICH following CAS compared with CEA.
he exact incidence of HPS without ICH following CEA is
ot known but is estimated at 0.75% to 3% (24,25). Meyers et
l. (15) studied the incidence of HPS prospectively in endo-
ascularly treated patients and found an incidence of 5%, but in
heir series only 66 of 140 patients had had carotid interven-
ions, so their results may be inaccurate. Initially, we did not
ecord data prospectively on the occurrence of unilateral head-
che, nausea, and vomiting, and therefore our results likely
nderestimate the occurrence of HPS without ICH. It seems
ikely that the true incidence of HPS without ICH is closer to
% to 5% rather than the 1.1% we found. This highlights a
imitation of our study, which despite being based on prospec-
ive collection of information for the database, was a retrospec-
ive review. Our estimate, however, of the incidence of symp-
omatic ICH is accurate. This is because the clinical
anifestations of ICH are obvious and often catastrophic and
ecause all peri- and postoperative neurological deficits and
vents were collected into the database.
The most widely held view is that HPS occurs as a result of
mpaired autoregulation of cerebral blood flow (CBF) (4,7).
he chronic low-flow state induced by severe carotid disease
esults in a compensatory dilation of cerebral vessels distal to
he stenosis as part of the normal autoregulatory response to
aintain adequate CBF. As a result of chronic dilation, the
essels lose their ability to autoregulate vascular resistance in
esponse to changes in blood pressure. This results in increased
BF after recanalization; thus the term “hyperperfusion.” This
odel of HPS is supported by findings of noninvasive testinguch as transcranial Doppler ultrasound (TCD), by histopa- ohology on postmortem examinations, and by experimental
tudies in animal models (9,10,24,26).
The typical clinical finding of HPS following CEA is an
psilateral throbbing headache in a facial, temporal, or
etro-orbital distribution, which may be the only manifes-
ation of the syndrome (9,11,23). Other common symptoms
nclude nausea, vomiting, focal deficits, and seizures (focal
r generalized) (5,6,11). Postprocedural hypertension is a
ritical, though not essential, finding associated with HPS
5,6,11). Four of our patients had this typical clinical
attern, which suggests that they did indeed have the HPS
espite the fact that we did not measure CBF. In our series,
CH developed on the third and fifth postoperative days,
espectively. This is in keeping with a peak incidence
etween the third and fifth postoperative days (range 2 to 17
ays) observed following CEA (11). There have been cases
bserved immediately after surgery, as occurred in one of
ur patients (5,6,11). Following CEA, ICH carries a 37% to
0% mortality rate and a 20% to 37% risk of poor recovery
n survivors (3,23). The outcomes in our series are in
eeping with the grim prognosis associated with ICH.
Risk factors for developing HPS following CEA have been
dentified (5,6,8,9,11,20). The essential risk factor is the
resence of a critical ICA stenosis 90% (9,11,24,27). Other
mportant risk factors following CEA include severe contralat-
ral ICA disease, poor collateral flow, hypertension, and recent
troke or ischemia (5,6,8,9,11,20,24). In our series, all patients
ith HPS had these same risk factors, which is in keeping with
he hypothesis that the mechanisms of hyperperfusion are
imilar between CEA and CAS. Although CAS and CEA are
arkedly different procedures, the resultant changes in cerebral
ascular physiology are similar. In addition to the above
linical/anatomical predictors, TCD may be able to predict
hich patients are at increased risk of HPS and ICH by
easuring mean flow velocities in the ipsilateral middle cere-
ral artery (MCA) (24).
Safety concerns have been raised about the effects of
nticoagulants and antiplatelet agents and the risk of ICH
ollowing CEA, but no causal link has been found (11,25).
imilarly, although anticoagulants and antiplatelet agents
re used more frequently following CAS than following
EA, there did not appear to be an increased risk of ICH
ollowing their use in our study. Nonetheless, we avoided
xcessive anticoagulation intraprocedurally, and we did not
ontinue anticoagulants postoperatively. These two factors
lone might explain the lower incidence of ICH in our series
ompared with those previously discussed (15,16).
The progression of HPS to ICH is associated with an
xtremely poor prognosis. Prevention is critical. The most
mportant component of perioperative management is vig-
lant monitoring and control of systemic blood pressure
3,6,10,11,24,25,28). It has been suggested that even blood
ressures in the “normal” range may be deleterious in
atients at high risk for HPS (3,11,28). For blood pressure
ontrol after CAS, beta-blockers have several advantages
ver other antihypertensive agents (e.g., hydralazine), which
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May 5, 2004:1596–601 Hyperperfusion Syndrome Following Carotid Stentingay further increase cerebral blood flow, leading to a
ounterproductive effect, or nitrates, which may cause head-
che (25). Careful monitoring of blood pressures should
ontinue for at least two weeks following the procedure.
his can be accomplished using either home nursing visits
r over-the-counter automated blood pressure monitors.
lthough we did not systematically measure changes in
BF with lowering of blood pressure in our patients, the
atients did respond clinically to lower pressures (24,28).
Additional efforts to reduce the risk of ICH may include
imiting the duration of balloon inflation and employing
mboli-prevention devices. These measures help minimize
rocedural brain ischemia, which potentiates the risk of HPS
nd ICH (4,24,26). If patients develop clinical symptoms
uggestive of HPS or if patients have a documented elevation
n MCA velocities to twice their baseline value we typically
ithhold antiplatelet agents until symptoms have resolved and
he blood pressure is optimally controlled. Although there are
o outcome data to support this approach following CAS, we
elieve that the risks of this approach are far outweighed by the
otential consequences of ICH. In our two patients who
resented with HPS but without ICH we were able to control
rterial pressures within hours, so a single missed dose of
spirin and Plavix was not significant in terms of precipitating
cute stent thrombosis.
onclusions. Hyperperfusion syndrome is a potentially dev-
stating complication of percutaneous carotid revascularization
nd has become increasingly more important as the rates of
schemic complications have declined. High-risk patients in-
lude those with a severe ICA stenosis, severe contralateral
CA stenosis or occlusion, poor intracerebral collaterals, ele-
ated MCA velocities following the procedure, and perioper-
tive hypertension. Careful screening to identify high-risk
atients, vigilant postoperative monitoring for signs of HPS,
nd aggressive management of postoperative blood pressure are
mportant steps in both preventing and minimizing the impact
f this potentially devastating complication.
eprint requests and correspondence: Dr. Jay S. Yadav, Direc-
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